Avant Diagnostics, Inc. (AVDX) Leading the Next Advance in

New Post Public Reply Private Reply Replies (0) Message Board
QualityStocks
Avant Diagnostics, Inc. (AVDX) Leading the Next Advance in the ‘War on Cancer’ through the Development of OvaDx®

The American Cancer Society estimates that about 21,290 new cases of ovarian cancer will be diagnosed in 2015, and roughly 14,180 women will die from the illness within the United States. These figures outline the severity of ovarian cancer, which is currently the eighth most common cancer among women, as well as the fifth leading cause of cancer-related death among women, according to data from SEER. Over the past forty years, mortality rates for ovarian cancer have recorded a mild decline as a result of the ongoing ‘War on Cancer’, but these improvements pale in comparison to the progress made on some other forms of the disease. Today, nearly half of all cancer patients can expect to live for five or more years after diagnosis with proper treatment.

With this data in mind, the question regarding ovarian cancer becomes clear: Why hasn’t more progress been made toward improving survivability? To understand the answer to this question, one needs to take a closer look at the illness.

Ovarian cancer begins when healthy cells in an ovary mutate and begin to grow uncontrollably, forming a mass known as a tumor. Tumors come in two basic forms – cancerous and benign. While benign tumors can cause problems by continuing to grow, cancerous tumors are, by far, the more dangerous form. Cancerous tumors on the ovaries are malignant, meaning they can continue to grow and spread to other parts of the body. For this reason, catching the disease in its early stages is paramount to improving survivability rates.

When diagnosed early, ovarian cancer is actually an extremely survivable disease. According to data from the American Cancer Society, individuals with ovarian cancer that’s diagnosed in stage I boast a five-year survivability rate of approximately 90 percent. However, this outlook is significantly worse when the illness isn’t discovered until the later stages. In stage II, the five-year survivability rate for invasive epithelial ovarian cancer, which accounts for roughly 85 percent of all cancers of the ovaries, falls to 70 percent. In stage III, survivability is just 39 percent.

With the importance of early detection clearly illustrated, a massively underserved indication within the diagnostic market becomes evident. The National Ovarian Cancer Coalition reports that almost 70 percent of women diagnosed with the common epithelial ovarian cancer are not diagnosed until the disease is advanced in stage.

Current ovarian cancer detection methods are hampered by a variety of factors. The simplest check, a pelvic exam, consists of a health care professional feeling the ovaries and uterus for size, shape and consistency. While these tests are relatively effective for some reproductive system cancers, most early ovarian tumors are difficult or impossible for even the most skilled examiner to feel. Screening tests and exams are also used for detection in people who don’t display any symptoms. However, both transvaginal ultrasound (TVUS) and the CA-125 blood test have drawbacks.

In the case of TVUS, sound waves are used to study the reproductive system. These waves can help physicians locate tumors on the ovaries, but they doesn’t help determine if the mass is cancerous or benign. The CA-125 blood test, on the other hand, checks the patient’s blood for high levels of the CA-125 protein, which is commonly associated with ovarian cancer. The effectiveness of this test is also hindered, because many common conditions other than cancer can cause high levels of CA-125.

Avant Diagnostics, Inc. (OTCQB: AVDX) is developing a novel approach to ovarian cancer screening that has the potential to fill this underserved need in the medical community. OvaDX® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. In clinical research, OvaDX has displayed high sensitivity and specificity for all types and stages of ovarian cancer – including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Following FDA approval, Avant plans to market OvaDx to doctors as a supplement to existing tests for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

As of its latest update, Avant had received FDA approval for ovarian cancer specimens to be used in a forthcoming validation study to support a pre-submission package to the FDA. After this package is submitted and reviewed, the company will look to commence the OvaDx 510(k) trial, which it plans to conduct in a double-blinded environment supervised by an independent clinical research organization.

For more information, visit www.avantdiagnostics.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

Avant Diagnostics, Inc. (AVDX) Stock Research Links

AVDX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 58

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading

Top 5 Most Recently Viewed Articles

Freddie Mac's 30-Year Mortgage Rate Decreases Slightly

Updated Category News Views 219

Freddie Mac Reports on Mortgage Rates In recent reports from Freddie Mac, there's good news for potential homebuyers. The 30-year fixed-rate mortgage (FRM) has seen a slight decline, which is a welcome change in a fluctuating market. This current value sits at an average of 6.64%, reflecting a small drop from the previous week's average of 6.65%. Understanding the Current...

Continue Reading
Sports.com Partners with SEGG Media for Soccerex Event

Updated Category News Views 251

Sports.com Joins SEGG Media as Title Sponsor at Soccerex Miami 2025 MIAMI BEACH, Fla. — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) has officially announced that Sports.com will take on the role of Title Sponsor for the engaging Soccerex Miami event happening at the Miami Beach Convention Center. This sponsorship reflects a significant commitment to promoting...

Continue Reading
Gastech 2025: A Global Convergence for Energy Innovations

Updated Category News Views 249

Gastech 2025 Unites the World of Energy Innovation Gastech 2025 welcomes more than 50,000 attendees from over 150 countries, establishing Milan as the global center for critical dialogues on energy supply, transformation, and innovation. This event has become a vital platform for high-level conversations that shape the future of energy. Leadership at Gastech 2025...

Continue Reading
Baird Confirms Outperform Rating for Costco Amidst Strong Growth

Updated Category News Views 68

Strong Sales Performance Driving Costco's Success Baird has reaffirmed its Outperform rating for Costco Wholesale (NASDAQ: COST), while upholding a price target of $975. The firm's latest insights indicate that Costco's global core comparable sales, excluding gas and foreign exchange influences, have surged by 8.9%. Such a rise is significant and demonstrates the...

Continue Reading
Celebrating a Decade of DNBSEQ™: Innovations and Impact

Updated Category News Views 290

Celebrating a Decade of DNBSEQ™ Technology MGI Tech Co., Ltd. (NASDAQ: MGI) is thrilled to celebrate ten years of its revolutionary DNBSEQ™ sequencing technology. This milestone marks a significant journey in transforming the landscape of genomics, offering solutions that not only enhance scientific research but also make genomic information more accessible to a...

Continue Reading